Insider trade

Officer sold ~$243K of JAZZ shares in the open market

Traded Feb 26, 2026 · Filed Mar 3, 2026

Why it stands out

Jazz Pharmaceuticals's SVP, Chief Accounting Officer sold $243K of Jazz Pharmaceuticals shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$243,222

Shares × reported transaction price

Timing vs results

2 days after results of Feb 24, 2026, 68 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references tax withholding

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−0.4%	−0.5%	+0.1%
30 days	+0.1%	−3.6%	+3.8%
90 days	+24.6%	+11.5%	+13.1%
180 days	+34.3%	+12.8%	+21.5%

Past results only. Not a forecast.

Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.7300 to $194.4100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.